Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
You MISSED the biggest takeaway. This fucking Crook Otiko BORROWED $700k from the company. He is probably going to have the $700K forgiven again like the last $300K he borrowed from the company and never repaid. Everyone needs to call the SEC and filing a complaint on this piece of shit thief!!!
No bad Otiko, no bad at all. Looking great with this filling. Hats down to him. I guess I will leave the Doc alone for a while. He is working well and company has proven to have revenue. Not doubts ViaDerma is one of the few left as safe heaven to invest long term. I guess we’ll be fine in here
https://www.otcmarkets.com/otcapi/company/financial-report/402037/content
Nothing on Consolidated Income Statements looks like payment for product production.
Quick Takeaways
Cash increased $367K, not around $1.2M, with $700K of Accounts Receivable appearing to have only been renamed "Receivable from related party", versus actual receipt of back licensing payments ($1.2M payment receipt reported on X on 2/1/24).
Revenue, like all of 2023, appears to reflect 10 state licensing agreements, deviating from reported state agreement counts, with latest being 14 states (as reported in 10/24/23 PR). This should not be related to Dr's over-the-top, personal bonus, contract revenue provision, whereas the total revenue would still be reflected ($210K) partially offset by expense ($63K) for the bonus provision.
Trickle of online sales continues.
Convertible notes remains $323K.
At least a quarterly was on time for the first time in over a year, and Cash increased $350K+.
1Q24 Financial Report has been posted.
https://www.otcmarkets.com/otcapi/company/financial-report/402037/content
I think he's beached
I just want to see the dude that has access to the IR and insider info. I forgot his user name but he called out the filling last time in a timely manner because IR told him such. Why isn’t he coming around this time?
Anyways, does anyone know if ORCA made it from the E.R?
$.0088 I'm expecting something very good very soon! Believe it, don't, I don't give a .....!
Not worried one bit, nor am I whining!
Little less than 20.00
Oh wow share price is in the green today!!!
What is 2,105 shares worth? Like $2?
Market really loves this stock!!!
Where I disagree is him hiring assistants/employees/help. I mean, this guy has done it all completely ALONE. Closed the Dubai deal, Nigeria, etc, all completely by himself!
No need to hire help! He will organically grow this $8.5M company to $100M on his own!
He doesn’t even need CPAs because he doesn’t file FINs, pretty damn efficient!!
Ohh yeah, Dubai and Mexico. He is fighting hard for us. We gotta be paytient… Marijuana is legal now folks, use it… Doc O. Must be stoned now with lots of VDRM logs and drawings all over his granny’s basement now
Viva ViaDerma!!! Note: When $hit hits the fan, please don’t panic, keep smoking weee like the Doc and y’all be fine. LMAOOOO
Ohh my gosh, wait, what’s this ? Mates, I got $hit all over, gosh, the $hit already hit the fan!
OTIKO where at you?
Yeah, I agree, it is super deals time. He probably won’t be capable to sleep either of so many international paper work and deals he has landed already. He will need to hire a few assistants, happy ending assistants, massage therapist assistant, etc. very stressful agenda he might be now. International deals in Dubai, serious business there. Viva ViaDerma
Board took a turn hahaha
Homeboy wants the butt cheeks!!!!
Hahahhahahha
This is gold
Make sense , he may have gone overseas to make atleast 1B deal.
Let's hope for something good this week GLTA
Maybe he’s late I long because he’s out closing international deals. Super busy getting large healthcare networks to sign on the dotted line. Just closing deals left and right
God hear ya mate, God hear ya
Bad weed never dies!!! 😂 trust me, that dude is healthier than anyone of us…
I am going out on a limb to say this week could/should be pivotal. IF the 1st quarter filing is done by Wednesday it should indicate the received licensing money that was tweeted about on feb 1st of 1.2 million. also, it's possible/hopefully to see any indication of the international deals being shipped in 1st quarter and maybe some other sprinklings of good news.
Wondering he is alive or travelling in eastern coutries.
He may be dead since no filing.
Hope is a sin in OTCM
I also have been here for many years. Many false starts,,BUT I do believe that this is our year for great price and company improvements.
Ah I will still invest, I’ve bought and sold a dozen times over the last 4years or so.
Eventually this guy will want more money out of this and pump it (last big pump was intent sciences and Nupelo lol) just get a low avg share price.
I am mainly pointing out the truth so that people don’t actually fall flor this guy. He’s repeatedly lied for 10years now. Do NOT invest the shirt off your back into this clown
I did just hear such, from you! 😂 now, the $30K question is, from where did you hear it?
Best way to find out is to ask that dude to claim to have spoken well to an insider. The one who called out the financials day. I even forgot his username but we do have someone in here that the friend of his friend is an insider
You didn’t know that before. If you would have known such and still invested into it, then it would have been a good question to ask. I don’t think anyone sane would have pour money into someone’s part time gig. Unfortunately for me, I got to study well the doc, too late
New addition
5) Hopefully, there is noticeable quantity of Inventory (or any) shown on Balance Sheet, giving a measure of plausibility, no matter how slight, that there might be a deal on the horizon. (Credibility, Reputation & possible Results)
Hahahaha good stuff!
“Team”
“Around the clock”
Literally haven’t accomplished anything but washing money from one company to the other via “licensing fees” lol
Another classic from the Hall of Baloney, from 10/24/23 PR:
"...Our team is working around the clock to ensure operations, manufacturing, and product distribution are sound and ready to meet this growing demand around the world and fulfill purchase orders in the hundreds of thousands per country with the expectations to continually compound sales growth throughout 2024 and beyond."
Nah....probably reading message boards when it was called out.....
Actually, remember when he said there was “no more debt”, then the CPA found that there was “MORE DEBT” of around $200K lol, maybe that was a partial audit
Hahahhahahaha
This guy is terrified of auditing
Of course not....
Is insurance covering the purchase of Vitastem Ultra?😂
Does VDRM have ANY audited FINs, going back over the years?
Anyone care to opine on the trading activity. The pps is trickling down but the volume is light. I don't have level II to guage the activity. Do we have disgruntled investors jumping ship or people beating down the ask to buy cheap?
That speculation has been put out intermittently for years. It is just to the right of inconceivable, with $90+ price point for Vitastem Ultra. However, for all speculators and investors, oh, how I wish I would be proved wrong.
Has anyone heard that walmart maybe looking at it?
Stupidity for taking a man's word at face value with a sprinkling of greed and a lot of poor judgment.
Who knows…. Maybe the Dr is working on a $5 million dollar sale with a major chain like CVS or a company of the like???? One never knows…..
Yup. Makes you wonder if he is even working on this.
Why would we invest in someone’s part time gig they put zero effort into?
Guys Relax, some of you are jumping ahead too fast. Nobody is ripping off no one from ViaDerma. You have to understand that the Doc is not a business man or a deal breaker. He is doing the best he can and ViaDerma is his egg nest, his pride, his legacy. He is an immigrant and as such, he wouldn’t sell his legacy to a big pharmaceutical. I understand him now, even partnerships is out of the window. He won’t hire an experienced CEO either because his Ego and he won’t let nobody else to put hands onto something that has costed him so much effort to build. Only way I think he will succeed with this mentality is if he gets lucky. I am just waiting for the right spike to come and GTFO because OTIKO will never land a dollar land deal. He is treating ViaDerma like a grocery store and grocery stores only make cents
Followers
|
619
|
Posters
|
|
Posts (Today)
|
3
|
Posts (Total)
|
74597
|
Created
|
10/27/08
|
Type
|
Free
|
Moderators |
ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.
The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.
This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.
The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.
A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.
The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.
Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.
In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.
We are developing products in the following fields of use;
Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.
Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.
Treats symptoms of Influenza which is a$4B/ year global market: Common
Diabetic foot wounds.
Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.
Per 12/7/17 PR: The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments.
Per 1/23/18 PR: The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.
The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.
CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and Spray.
CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays, and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.
"What is Intellectual Property?" - A Publication by the World Intellectual Property Organization -
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |